CME: Renal Cell Carcinoma (RCC): Optimizing Pharmacotherapeutic and Interventional Management Strategies
Cost: FreeView Offer chevron_right
Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons and is responsible for the vast majority – 85% – of all renal cancers. With risk factors that include smoking, obesity, cadmium exposure, older age, and genetics, the five year survival rate of those afflicted with kidney cancer overall is 68%. In part because there are not any clear early symptoms associated with kidney cancer, RCC is discovered predominantly after it has already progressed to advanced stages, with the brain, bones, lungs, and liver serving as some of the most common sites of metastases. RCC’s treatment depends on its stage and size, with surgeryutilized for localized tumors and systemic therapy a mainstay of care for metastatic disease.
By the end of the session the participant will be able to:
- Describe the role of the immune system in cancer and cancer therapy in RCC
- Describe immuno- and monoclonal therapies mechanisms of action and the biochemical pathways they impact in RCC
- Identify the treatment modalities currently available for management of RCC and apply them to patient cases using evidence-based medicine
- Describe the differences in safety profiles between conventional cytotoxic, monoclonal, and immunotherapy in RCC
- Describe methods for combatting barriers to patient care, including fostering a strong provider-patient relationship
The following healthcare professionals: medical oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.